PMID- 25267060
OWN - NLM
STAT- MEDLINE
DCOM- 20150106
LR  - 20221207
IS  - 1432-1211 (Electronic)
IS  - 0093-7711 (Linking)
VI  - 66
IP  - 12
DP  - 2014 Dec
TI  - Cervical cancer in Indian women reveals contrasting association among common 
      sub-family of HLA class I alleles.
PG  - 683-91
LID - 10.1007/s00251-014-0805-2 [doi]
AB  - We studied the relationship between human leukocyte antigen (HLA) class I alleles 
      and cervical cancer among Indian women. Seventy-five cervical cancer cases were 
      compared with 175 noncancer controls. Cervical biopsy tissue specimen from cancer 
      cases and cervical swab specimen from controls were collected for HPV detection 
      and typing. Blood was taken for HLA typing by PCR-SSOP method. The impact of HLA 
      class I alleles on cervical cancer risk was evaluated using StatCalc program (Epi 
      Info version 6.0.4. CDC Atlanta, GA, USA), and confirmed with Bonferroni 
      correction. Results revealed HLA-B*37, HLA-B*58 were associated significantly 
      with increased risk while HLA-B*40 with decreased risk for cervical cancer. At 
      high-resolution analysis after Bonferroni correction, HLA-B*37:01 allele was 
      associated with increased risk, whereas HLA-B*40:06 was with decreased risk for 
      cervical cancer. HLA-B*37:01 and HLA-B*40:06 belong to the same superfamily of 
      HLA-B44. In silico analysis revealed different binding affinities of HLA-B*37:01 
      and HLA-B*40:06 for the epitopes predicted for E6 and L1 proteins of HPV16. The 
      higher binding affinity of epitopes to B*40:06, as revealed by docking studies, 
      supports the hypothesis that this allele is able to present the antigenic 
      peptides more efficiently than B*37:01 and thereby can protect the carriers from 
      the risk of cervical cancer. Thus, there is a clear indication that HLA plays an 
      important role in the development of cervical cancer in HPV-infected women. 
      Identification of these factors in high-risk HPV-infected women may help in 
      reducing the cervical cancer burden in India.
FAU - Gokhale, Priyanka
AU  - Gokhale P
AD  - National Institute for Research in Reproductive Health, Mumbai, India.
FAU - Mania-Pramanik, Jayanti
AU  - Mania-Pramanik J
FAU - Sonawani, Archana
AU  - Sonawani A
FAU - Idicula-Thomas, Susan
AU  - Idicula-Thomas S
FAU - Kerkar, Shilpa
AU  - Kerkar S
FAU - Tongaonkar, Hemant
AU  - Tongaonkar H
FAU - Chaudhari, Hemangi
AU  - Chaudhari H
FAU - Warke, Himangi
AU  - Warke H
FAU - Salvi, Vinita
AU  - Salvi V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140930
PL  - United States
TA  - Immunogenetics
JT  - Immunogenetics
JID - 0420404
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Alleles
MH  - Alphapapillomavirus/classification/genetics
MH  - Case-Control Studies
MH  - Epitopes/chemistry/immunology/metabolism
MH  - Female
MH  - Gene Frequency
MH  - *Genetic Predisposition to Disease
MH  - Histocompatibility Antigens Class I/chemistry/*genetics/immunology/metabolism
MH  - Humans
MH  - India
MH  - Middle Aged
MH  - Models, Molecular
MH  - Protein Binding
MH  - Protein Conformation
MH  - Reproducibility of Results
MH  - Uterine Cervical Neoplasms/*genetics/immunology/virology
MH  - White People/*genetics
EDAT- 2014/10/01 06:00
MHDA- 2015/01/07 06:00
CRDT- 2014/10/01 06:00
PHST- 2014/07/03 00:00 [received]
PHST- 2014/09/08 00:00 [accepted]
PHST- 2014/10/01 06:00 [entrez]
PHST- 2014/10/01 06:00 [pubmed]
PHST- 2015/01/07 06:00 [medline]
AID - 10.1007/s00251-014-0805-2 [doi]
PST - ppublish
SO  - Immunogenetics. 2014 Dec;66(12):683-91. doi: 10.1007/s00251-014-0805-2. Epub 2014 
      Sep 30.